SCHEMBL2572024

SCHEMBL2572024

Cc1cc(Cl)ccc1NC(=O)Nc1cn(Cc2ccccc2)c(C(=O)O)n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 6/20 0.48
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
BRD4 O60885 1/20 0.44
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDR P35968 1/20 0.42
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
GRIK1 P39086 1/20 0.41
GBA1 P04062 1/20 0.41
RAB9A P51151 1/20 0.41
NR1I2 O75469 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881477 0.88 GRIK1 (0.44) P2RX7KMT2AGAAMAPTTP53
SCHEMBL1595904 0.85 MAPT (0.42) LMNAPOLBKMT2ASMN1; SMN2MAPT
SCHEMBL2572026 0.85 P2RX7 (0.48) P2RX7LMNAPOLBKMT2ASMN1; SMN2
SCHEMBL13197798 0.85 P2RX7 (0.45) P2RX7LMNAPOLBKMT2ASMN1; SMN2
SCHEMBL13197922 0.85 LMNA (0.48) LMNASMN1; SMN2GAAMAPT
SCHEMBL2565935 0.84 ALOX5 (0.41) SMN1; SMN2GAAL3MBTL1MAPTGRIK1
SCHEMBL2569122 0.84 MAPT (0.40) P2RX7LMNAPOLBKMT2ASMN1; SMN2
SCHEMBL2572465 0.84 MAPK1 (0.39) POLBKMT2ASMN1; SMN2L3MBTL1KDR
SCHEMBL1594449 0.84 MEN1 (0.41) LMNAPOLBKMT2ASMN1; SMN2KDR
SCHEMBL2570872 0.84 MAPK1 (0.39) POLBKMT2ASMN1; SMN2BRD4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 EP disclosed
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 EP disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 P2RX7 1224/4885LMNA 3009/4885POLB 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.